265 related articles for article (PubMed ID: 11863115)
1. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels.
Colleoni M; Rocca A; Sandri MT; Zorzino L; Masci G; Nolè F; Peruzzotti G; Robertson C; Orlando L; Cinieri S; de BF; Viale G; Goldhirsch A
Ann Oncol; 2002 Jan; 13(1):73-80. PubMed ID: 11863115
[TBL] [Abstract][Full Text] [Related]
2. Metronomic chemotherapy in metastatic breast cancer: impact on VEGF.
El-Arab LR; Swellam M; El Mahdy MM
J Egypt Natl Canc Inst; 2012 Mar; 24(1):15-22. PubMed ID: 23587228
[TBL] [Abstract][Full Text] [Related]
3. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects.
Colleoni M; Orlando L; Sanna G; Rocca A; Maisonneuve P; Peruzzotti G; Ghisini R; Sandri MT; Zorzino L; Nolè F; Viale G; Goldhirsch A
Ann Oncol; 2006 Feb; 17(2):232-8. PubMed ID: 16322118
[TBL] [Abstract][Full Text] [Related]
4. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer.
Orlando L; Cardillo A; Rocca A; Balduzzi A; Ghisini R; Peruzzotti G; Goldhirsch A; D'Alessandro C; Cinieri S; Preda L; Colleoni M
Anticancer Drugs; 2006 Sep; 17(8):961-7. PubMed ID: 16940806
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
Wong NS; Buckman RA; Clemons M; Verma S; Dent S; Trudeau ME; Roche K; Ebos J; Kerbel R; Deboer GE; Sutherland DJ; Emmenegger U; Slingerland J; Gardner S; Pritchard KI
J Clin Oncol; 2010 Feb; 28(5):723-30. PubMed ID: 20026801
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of metronomic chemotherapy as salvage therapy for patients with metastatic breast cancer.
Salem DA; Gado NM; Abdelaziz NN; Essa AE; Abdelhafeez ZM; Kamel TH
J Egypt Natl Canc Inst; 2008 Jun; 20(2):134-40. PubMed ID: 20029469
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy and angiogenesis in advanced cancer: vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer.
Lissoni P; Fugamalli E; Malugani F; Ardizzoia A; Secondino S; Tancini G; Gardani GS
Int J Biol Markers; 2000; 15(4):308-11. PubMed ID: 11192826
[TBL] [Abstract][Full Text] [Related]
9. Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer.
Coskun U; Günel N; Toruner FB; Sancak B; Onuk E; Bayram O; Cengiz O; Yilmaz E; Elbeg S; Ozkan S
Neoplasma; 2003; 50(1):41-6. PubMed ID: 12687277
[TBL] [Abstract][Full Text] [Related]
10. Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma.
Gebbia V; Boussen H; Valerio MR
Anticancer Res; 2012 Feb; 32(2):529-36. PubMed ID: 22287742
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study.
Mariani G; Petrelli F; Zambetti M; Moliterni A; Fasolo A; Marchiano A; Valagussa P; Gianni L
Clin Breast Cancer; 2006 Oct; 7(4):321-5. PubMed ID: 17092399
[TBL] [Abstract][Full Text] [Related]
12. Serum vascular endothelial growth factor is often elevated in disseminated cancer.
Salven P; Mänpää H; Orpana A; Alitalo K; Joensuu H
Clin Cancer Res; 1997 May; 3(5):647-51. PubMed ID: 9815732
[TBL] [Abstract][Full Text] [Related]
13. Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes.
Kalbakis K; Kouroussis C; Kakolyris S; Mavroudis D; Souglakos J; Agelaki S; Vamvakas L; Christodoulakis M; Stylianou K; Georgoulias V
Br J Cancer; 2001 Sep; 85(6):798-802. PubMed ID: 11556827
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
15. Serum VEGF levels in women with a benign breast tumor or breast cancer.
Salven P; Perhoniemi V; Tykkä H; Mäenpää H; Joensuu H
Breast Cancer Res Treat; 1999 Jan; 53(2):161-6. PubMed ID: 10326793
[TBL] [Abstract][Full Text] [Related]
16. Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients.
Benoy I; Salgado R; Colpaert C; Weytjens R; Vermeulen PB; Dirix LY
Clin Breast Cancer; 2002 Jan; 2(4):311-5. PubMed ID: 11899364
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.
Kraft A; Weindel K; Ochs A; Marth C; Zmija J; Schumacher P; Unger C; Marmé D; Gastl G
Cancer; 1999 Jan; 85(1):178-87. PubMed ID: 9921991
[TBL] [Abstract][Full Text] [Related]
18. Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics.
Mayer EL; Isakoff SJ; Klement G; Downing SR; Chen WY; Hannagan K; Gelman R; Winer EP; Burstein HJ
Breast Cancer Res Treat; 2012 Nov; 136(1):169-78. PubMed ID: 23001754
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients.
Bachelot T; Ray-Coquard I; Menetrier-Caux C; Rastkha M; Duc A; Blay JY
Br J Cancer; 2003 Jun; 88(11):1721-6. PubMed ID: 12771987
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Toxicity of Metronomic Chemotherapy in Metastatic Breast Cancer: Egyptian Experience.
Hussein MM; Gaafar RM; Abdel-Warith AM; Ahmed WA; Allahloubi NMA; Salem SE; Abdel-Salam IM
Clin Breast Cancer; 2017 Dec; 17(8):618-628. PubMed ID: 28625341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
